New company applies regenerative medicine to corneal transplantation

January 8, 2013

Ocular Systems, Inc. (OSI), Wake Forest Baptist Medical Center and the North Carolina Eye Bank have formed a new company based on a promising new technology aimed at engineering replacement corneas in the lab for transplantation.

"The global need for for transplantation far exceeds the supply," said Dean Vavra, director of the North Carolina Eye Bank. "We are excited to be part of this innovative approach to sight restoration that has the potential to increase the availability of corneal tissue."

The new approach, not yet tested in patients, involves isolating cells from "banked" donor to grow replacement corneal tissue in the lab. The advantage is that cells from a single donor could potentially benefit multiple patients with impaired vision.

The company, formed by OSI, the sponsor and initial funder of the project, Wake Forest Baptist Medical Center, whose Institute for is conducting the research, and the North Carolina Eye Bank, is an example of the type of collaboration that is a strategic goal of the Piedmont Triad Research Park (PTRP). Also assisting with funding was the N.C. Biotechnology Center through a Collaborative Funding Grant.

The goal of the , known as HCEC, LLC (Human Cultured Endothelial Cells), is to advance the technology to the next level, which includes conducting the additional studies needed to apply to the U.S. to begin studies in human patients. This is expected to take several years.

"Today's announcement is the culmination of more than four years of planning and research," said OSI CEO Jerry Barker, who is the new company's managing partner. "We believe this innovative initiative has the potential to change the face of . The formation of HCEC, LLC will enable the team to expedite research and development efforts and move toward commercialization at a much faster pace."

The cornea is the transparent dome at the front of the eye that helps with focus. The cells that line the inside of the cornea, known as corneal endothelial cells (CECs), pump fluid out of the cornea. If these cells become diseased or damaged, vision is blurred. Because CECs cannot repair themselves, the standard treatment is to replace the cornea or cells with tissue from a cadaveric donor.

The current surgical technique is to replace a patient's damaged CECs with a very thin layer of tissue containing cells from a cadaveric donor cornea. The new cells pump fluid out of the cornea, restoring corneal clarity. With the advent of this procedure, there has been increased demand for donor tissue with healthy CECs. The goal of the new partnership is use regenerative medicine technology to meet this increased demand.

"The technique of bioengineering replacement tissues using and scaffolds can theoretically be applied to almost any tissue in the body," said Anthony Atala, M.D., director of the Wake Forest Institute for Regenerative Medicine. "We are delighted to be OSI's academic partner in this project."

"It is exciting that a collaboration based in the Piedmont Triad research Park, right her in Winston-Salem, has the potential to create products that can bring benefits to patients throughout the world," said Eric Tomlinson D.Sc., Ph.D., PTRP president and Chief Innovation Officer at Wake Forest Baptist. "This project is an example of the innovation that can be sparked in a research-park environment."

Shay Soker, Ph.D., professor of regenerative medicine at Wake Forest Baptist, is the lead scientist for the project. Other team members are Tracy Criswell, Ph.D., instructor of regenerative medicine; Ocular Systems Inc. scientists Jin San Choi, Ph.D., and Belinda Wagner, Ph.D.; and Wake Forest Baptist Department of Ophthalmology physicians Craig Greven, M.D., chair, Matthew Giegengack, M.D., assistant professor, and Keith Walter, M.D., associate professor.

Explore further: Regenerated cells may restore vision after corneal dysfunction

Related Stories

Regenerated cells may restore vision after corneal dysfunction

June 14, 2012
Regenerative medicine, or the use of specially grown tissues and cells to treat injuries and diseases, has been successful in treating disorders of a number of organs, including heart, pancreas, and cartilage. However, efforts ...

Development of new cornea endothelial cell lines provides powerful tool for understanding corneal cell biology

December 27, 2012
Human corneal endothelial cells (HCEnCs) form a monolayer of hexagonal cells whose main function is to maintain corneal clarity by regulating corneal hydration. Cell loss due to aging or corneal endothelial disorders, such ...

Engineered cornea more resistant to chemical injury

May 28, 2012
(Medical Xpress) -- A new study from the University of Reading has established that a prosthetic cornea made from human cells is the best model for testing how irritants and toxins cause eye injuries.

Recommended for you

Combination of type 2 diabetes and sleep apnoea indicates eyesight loss within four years

July 4, 2017
Research led by the University of Birmingham has discovered that patients who suffer from both Type 2 diabetes and obstructive sleep apnoea are at greater risk of developing a condition that leads to blindness within an average ...

Nearly 60% of pinkeye patients receive antibiotic eye drops, but they're seldom necessary

June 28, 2017
A new study suggests that most people with acute conjunctivitis, or pinkeye, are getting the wrong treatment.

Magnetic implants used to treat 'dancing eyes'

June 26, 2017
A research team has successfully used magnets implanted behind a person's eyes to treat nystagmus, a condition characterised by involuntary eye movements.

Drug shows promise against vision-robbing disease in seniors

June 21, 2017
An experimental drug is showing promise against an untreatable eye disease that blinds older adults—and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision.

Reproducing a retinal disease on a chip

June 15, 2017
Approximately 80% of all sensory input is received via the eyes, so suffering from chronic retinal diseases that lead to blindness causes a significant decrease in the quality of life (QOL). And because retinal diseases are ...

New gene therapy for vision loss proven safe in humans

May 16, 2017
In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to introduce a therapeutic gene into the eye is safe and that it ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.